Blastic natural killer cell lymphoma/leukaemia in a cat.

JFMS Open Rep

Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan.

Published: July 2019

Case Summary: A 7-year-old mixed-breed cat presented with subcutaneous oedema and erythema extending from the right axilla to the abdomen. Fine-needle aspiration of the subcutaneous lesion revealed large, atypical, round cells. A clonality analysis for the T-cell receptor-gamma and immunoglobulin heavy chain genes showed no clonal rearrangement. The presumed diagnosis was lymphoma and the cat was treated with prednisolone and L-asparaginase but died 78 days after initial treatment. At necropsy, an oedematous subcutaneous mass in the right axilla, hepatomegaly, splenomegaly and lymphadenopathy of the mediastinum and left axilla were observed. Histopathological examination revealed diffuse infiltration of large atypical round cells in the subcutaneous mass, liver, spleen, lymph nodes and bone marrow. Immunohistochemically, the tumour cells were strongly positive for CD56, and negative for CD3, CD20, CD79a, CD57, granzyme B and perforin. Based on these findings, the cat was diagnosed with blastic natural killer (NK) cell lymphoma/leukaemia.

Relevance And Novel Information: Here, we report the pathological and clinical findings of NK cell lymphoma/leukaemia in a cat. The antibody for human CD56, a diagnostic marker for human NK cell neoplasms, showed cross-reactivity with feline CD56 by immunohistochemistry and Western blotting analysis. The antibody could be a useful diagnostic marker for feline NK cell neoplasms.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628536PMC
http://dx.doi.org/10.1177/2055116919863080DOI Listing

Publication Analysis

Top Keywords

blastic natural
8
natural killer
8
killer cell
8
cell lymphoma/leukaemia
8
lymphoma/leukaemia cat
8
large atypical
8
atypical round
8
round cells
8
subcutaneous mass
8
diagnostic marker
8

Similar Publications

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and often life-threatening complex hematologic malignancy that can commonly infiltrate the skin, lymph nodes, central nervous system, and bone marrow. In the setting of the infrequency of confirmed diagnoses of BPDCN, and given limited prospective studies, it has been associated with lackluster outcomes with a median overall survival between 9 and 23 months. We herein discuss our experience treating five consecutive patients with BPDCN at our center since the approval of TAG.

View Article and Find Full Text PDF

Blastic plasmacytoid dendritic cell neoplasm: Extensive disease, Langer lines, and blood burden in a retrospective study of 66 cases.

J Am Acad Dermatol

November 2024

Department of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article and Find Full Text PDF
Article Synopsis
  • Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is a rare and aggressive cancer that arises from dendritic cells and is known for its poor prognosis and unique surface markers (CD4 and CD56).
  • The disease has had various names over time, highlighting the complications in understanding its origin and diagnosing it, particularly due to similarities with other conditions like acute myeloid leukemia (AML) and histiocytic sarcoma (HS).
  • A case study of a 42-year-old male revealed diagnostic challenges, as initial suspicions of BPDCN were complicated by conflict from pathologists, leading to ineffective treatment and a rapid decline in the patient’s condition.
View Article and Find Full Text PDF

[Blastic plasmacytoid dendritic cell neoplasm detected by F-FDG PET-CT: a case report].

Zhonghua Zhong Liu Za Zhi

August 2024

Department of Nuclear Medicine (PET-CT), Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China.

View Article and Find Full Text PDF

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy affecting multiple sites, most commonly the skin. About 10-20% of BPDCN cases are accompanied by hematological neoplasms. A 71-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP) 11 years prior (at 60 years of age), and dasatinib treatment was initiated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!